|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2004-9-24
|
|
pubmed:abstractText |
We hypothesized that the benefit from ramipril on cardiac events and on left ventricular end-systolic volume (ESVI) in the Angiotensin-converting enzyme inhibition Post-revascularization Study (APRES) randomized controlled trial (RCT) was associated with long-term improvement.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1097-6744
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
148
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
475-80
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15389235-Analysis of Variance,
pubmed-meshheading:15389235-Angina Pectoris,
pubmed-meshheading:15389235-Angioplasty, Balloon, Coronary,
pubmed-meshheading:15389235-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:15389235-Coronary Artery Bypass,
pubmed-meshheading:15389235-Follow-Up Studies,
pubmed-meshheading:15389235-Heart Diseases,
pubmed-meshheading:15389235-Heart Failure,
pubmed-meshheading:15389235-Hospitalization,
pubmed-meshheading:15389235-Humans,
pubmed-meshheading:15389235-Myocardial Infarction,
pubmed-meshheading:15389235-Proportional Hazards Models,
pubmed-meshheading:15389235-Ramipril,
pubmed-meshheading:15389235-Risk,
pubmed-meshheading:15389235-Ventricular Dysfunction, Left
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES).
|
|
pubmed:affiliation |
Heart Center, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark. kjol-h@dadlnet.dk
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
